Company Of The Day: Pfizer

+35.96%
Upside
44.08
Market
59.93
Trefis
PFE: Pfizer logo
PFE
Pfizer

What?

Pfizer (NYSE:PFE) plans to acquire Biohaven Pharmaceutical, a company that specializes in migraine treatments, in a deal valued at about $11.6 billion.

Why?

Relevant Articles
  1. Pfizer’s Peer Appears To Be A Better Pharmaceuticals Pick
  2. Should You Buy Pfizer Stock After An Upbeat Q2?
  3. Should You Buy Pfizer Stock Ahead of Its Q2 Results?
  4. Should You Buy, Sell, Or Hold Pfizer Stock At $52?
  5. Here’s A Better Pick Over FedEx Stock
  6. What To Expect From Pfizer’s Q1?

Pfizer is flush with cash from its Covid-19 vaccine and is looking at acquisitions to bolster revenue as vaccine sales peak off, with some of its top-selling drugs also set to go off patent.

So What?

We think Pfizer stock is undervalued. We value PFE at $63 per share, about 25% ahead of the current market price.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns May 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 PFE Return 1% -16% 52%
 S&P 500 Return -5% -17% 76%
 Trefis Multi-Strategy Portfolio -9% -25% 196%

[1] Month-to-date and year-to-date as of 5/12/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates